The global blood testing market size was valued at USD 100.7 billion in 2025 and is projected to grow from USD 107.8 billion in 2026 to USD 185.92 billion by 2034 at a CAGR of 7.05% during the forecast period 2026-2034. North America dominated the blood testing market with a market share of 38.5% in 2025.
The procedure of examining a person's blood to identify and track various medical disorders is called "blood testing" in the global market. In today's medicine, blood tests are crucial for disease diagnosis, treatment efficacy monitoring, and risk factor screening. Blood testing examines various components in the blood or counts different types of blood cells. Blood tests are prescribed to check disease pathogens or agents, check for antibodies or tumor markers, or see how well-desired treatments work. Blood tests help physicians evaluate the working conditions of organs, diagnose diseases and risk factors for heart disease, check if medicines are working, check for cases of infection or genetic conditions, and determine how well the blood is clotting. Blood tests take only a few minutes and can be done in any local hospital or clinic.
Download a Free Sample To learn more about this report,
The blood testing market is moving toward faster, more accurate, and patient-friendly diagnostics. One of the biggest trends is the growing use of point-of-care (POC) blood testing, which provides results within minutes and helps clinicians make quicker treatment decisions. Hospitals and diagnostic laboratories are also adopting AI-powered analyzers and laboratory automation to improve accuracy, reduce manual errors, and handle larger testing volumes.
Another important trend is the rapid development of liquid biopsy technology for cancer detection and monitoring. Blood-based tests are increasingly being evaluated as less invasive alternatives to traditional tissue biopsies, especially in oncology, although many next-generation screening applications are still undergoing large clinical validation studies.
The growing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer, is a major driver for the global blood testing market. According to the World Health Organization (WHO), chronic diseases account for approximately 60% of all deaths worldwide, with cardiovascular diseases alone responsible for about 17.9 million deaths each year. This escalating burden of chronic diseases necessitates regular blood testing for early diagnosis and management.
Additionally, cancer diagnosis and treatment often involve various blood tests to monitor patient health and treatment efficacy. The increasing adoption of personalized medicine, which relies heavily on blood biomarkers to tailor treatments to individual patients, further propels the market. Moreover, innovations in blood testing technology, such as the development of liquid biopsy for non-invasive cancer detection, are also expected to drive market growth. These advancements offer less invasive, quicker, and more accurate diagnostic options, encouraging more frequent testing and early detection of diseases.
High Costs and Regulatory Challenges
Despite the significant advancements and demand in the blood testing market, high costs and regulatory challenges remain substantial restraints. The development and deployment of advanced blood testing technologies often require substantial investment in research and development, leading to high costs for end-users.
Additionally, the stringent regulatory environment for blood testing products poses significant challenges. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose rigorous standards and lengthy approval processes to ensure the safety and efficacy of blood testing devices and assays. This regulatory scrutiny can delay the market entry of new products and increase the costs associated with compliance. Furthermore, variations in regulatory requirements across different regions add complexity for manufacturers aiming to launch their products globally. These factors can hinder market growth, especially for smaller companies and startups with limited resources.
The blood testing market has strong growth opportunities due to the increasing adoption of preventive healthcare and routine health screening programs across both developed and emerging economies. Rising demand for early disease detection, personalized medicine, and home-based blood collection services is creating new revenue streams for diagnostic providers. The expansion of artificial intelligence in laboratory diagnostics, growing investments in molecular diagnostics, and wider access to point-of-care testing are also supporting market expansion. Government screening initiatives for diabetes, cancer, and infectious diseases continue to increase testing volumes. Positive Impact: +9.8% to +12.6% market growth potential, +15% to +22% increase in preventive screening demand, +18% to +25% growth in home-based blood testing adoption, +20% to +28% increase in AI-enabled laboratory efficiency.
The blood testing market continues to face challenges from high costs of advanced diagnostic equipment, shortages of skilled laboratory professionals, and strict regulatory requirements for new test approvals. Maintaining sample quality during collection and transportation remains difficult, particularly in remote regions. Data privacy concerns associated with digital health platforms and inconsistent reimbursement policies in several countries can also slow adoption of advanced testing solutions. In addition, supply chain disruptions affecting reagents and laboratory consumables may impact testing capacity and turnaround times. Negative Impact: -5.5% to -8.7% reduction in adoption due to high equipment costs, -6% to -10% impact from workforce shortages, -4% to -7% delays caused by regulatory compliance, -3% to -6% decline in operational efficiency from supply chain disruptions.
The solutions segment dominates the blood testing market, accounting for 78.6% of the total market with a value of USD 79.15 billion. Its strong position is driven by the growing demand for integrated diagnostic platforms, laboratory management systems, and testing services across healthcare facilities. The segment is expected to grow at a CAGR of 7.58% during the forecast period. Meanwhile, the software segment holds a 21.4% market share, valued at USD 21.55 billion, and is projected to register a faster CAGR of 9.12%. This growth is supported by the increasing adoption of digital laboratory solutions, cloud-based data management, and artificial intelligence in diagnostic workflows.
Glucose testing is the largest test type segment, representing 27.8% of the market with a value of USD 27.99 billion and a CAGR of 8.46%, driven by the rising prevalence of diabetes and regular blood sugar monitoring. Lipid panel testing accounts for 19.3% of the market, valued at USD 19.44 billion, with a CAGR of 7.64%, supported by increasing cardiovascular disease screening. Thyroid stimulating hormone (TSH) testing holds a 15.7% share, reaching USD 15.81 billion, and is expected to grow at a CAGR of 8.08% due to rising awareness of thyroid disorders. Blood urea nitrogen (BUN) testing contributes 13.5%, valued at USD 13.59 billion, with a CAGR of 7.22%, reflecting demand for kidney function assessment. Prostate specific antigen (PSA) testing represents 12.1% of the market, worth USD 12.18 billion, and is forecast to expand at a CAGR of 6.91% because of increasing prostate cancer screening. The others segment accounts for 11.6%, valued at USD 11.68 billion, and is expected to grow at a CAGR of 6.83%, supported by a broad range of specialized blood tests.
The automated method leads the blood testing market with a 71.9% market share and a value of USD 72.4 billion. It is projected to grow at a CAGR of 8.35%, driven by the need for faster, more accurate, and high-volume laboratory testing. In comparison, the manual method holds a 28.1% share, valued at USD 28.3 billion, and is expected to grow at a CAGR of 6.42%. Manual testing continues to be used in smaller laboratories and facilities where advanced automation is less accessible.
Hospitals and clinics are the largest end-use segment, accounting for 44.7% of the blood testing market with a value of USD 45.01 billion. The segment is expected to grow at a CAGR of 7.48%, supported by the high number of routine diagnostic procedures and inpatient testing. Diagnostic centers hold a 32.9% market share, valued at USD 33.13 billion, and are projected to grow at a CAGR of 7.91% due to increasing demand for specialized diagnostic services. Remote testing represents 14.8% of the market, worth USD 14.9 billion, and is expected to record the fastest CAGR of 10.24%, driven by the rising adoption of home healthcare, telemedicine, and self-testing solutions. The others segment accounts for 7.6%, with a market value of USD 7.65 billion, and is forecast to grow at a CAGR of 6.37%, supported by research institutions, public health laboratories, and other healthcare settings.
Speak to an Analystto discuss market opportunities.
North America is the largest regional market for blood testing, accounting for 38.5% of the global market with a value of USD 38.77 billion in 2025. The region is projected to grow at a CAGR of 7.62% during the forecast period. Market growth is driven by the widespread adoption of advanced diagnostic technologies, a high prevalence of chronic diseases such as diabetes and cardiovascular disorders, well-established healthcare infrastructure, and increasing demand for preventive health screening. Rising investments in laboratory automation and precision medicine are also supporting market expansion across the region.
The United States is the largest contributor to the North American blood testing market, with an estimated market value of USD 34.10 billion in 2025. Market growth is driven by the high prevalence of chronic diseases, widespread adoption of preventive healthcare, advanced laboratory infrastructure, and strong reimbursement systems. Increasing demand for molecular diagnostics, precision medicine, and point-of-care testing continues to support market expansion across hospitals, diagnostic laboratories, and outpatient care facilities.
Canada is estimated to account for USD 4.67 billion in 2025 within the North American blood testing market. Growth is supported by universal healthcare coverage, increasing government investments in diagnostic services, rising adoption of laboratory automation, and expanding preventive screening programs. The growing elderly population and rising incidence of chronic diseases are also contributing to higher testing volumes.
Europe holds the second-largest share of the blood testing market, representing 28.4% of the global market with a value of USD 28.60 billion in 2025. The market is expected to expand at a CAGR of 8.74%, the highest among the major regions. Growth is supported by increasing government healthcare spending, expanding diagnostic screening programs, growing awareness of early disease detection, and rising adoption of molecular and genetic testing. The region also benefits from continuous technological advancements in clinical laboratories and favorable healthcare policies.
Germany is Europe's largest blood testing market, with an estimated market value of USD 6.55 billion in 2025. The country's market benefits from advanced healthcare infrastructure, strong clinical laboratory networks, high healthcare spending, and increasing adoption of innovative diagnostic technologies. Growing demand for early disease diagnosis and personalized medicine is further driving market growth.
The United Kingdom is estimated to reach USD 4.58 billion in 2025. Market growth is supported by the National Health Service (NHS), increasing preventive health screening initiatives, expanding digital pathology services, and rising demand for rapid diagnostic testing. Investments in genomic medicine and laboratory modernization also contribute to market development.
Latin America represents 6.1% of the global blood testing market, with a value of USD 6.14 billion in 2025. The region is forecast to grow at a CAGR of 6.92% over the forecast period. Market growth is supported by improving access to diagnostic services, expanding public healthcare initiatives, increasing awareness of routine health screening, and rising investments in healthcare infrastructure. The growing prevalence of diabetes and cardiovascular diseases is also contributing to higher demand for blood testing services.
Brazil is the leading blood testing market in Latin America, with an estimated market value of USD 2.89 billion in 2025. Market growth is supported by improving healthcare infrastructure, increasing private diagnostic laboratory investments, rising chronic disease prevalence, and expanding public health screening programs. Demand for automated laboratory testing continues to increase across urban healthcare centers.
The Middle East and Africa account for 4.4% of the global blood testing market, valued at USD 4.43 billion in 2025. The market is expected to grow at a CAGR of 6.38% during the forecast period. Growth is driven by ongoing healthcare infrastructure development, increasing government investments in diagnostic services, rising awareness of early disease detection, and expanding access to healthcare facilities. The growing burden of infectious diseases and chronic health conditions is also supporting the adoption of blood testing across the region.
Saudi Arabia is estimated to account for USD 1.33 billion in 2025 within the Middle East and Africa market. Growth is supported by Vision 2030 healthcare transformation initiatives, increasing investments in modern hospitals and diagnostic laboratories, growing adoption of digital healthcare technologies, and rising demand for early disease detection.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com